In HER2- low breast cancer, the dense extracellular matrix may limit drug penetration through its physical barrier effect and weaken the efficacy of chemotherapy by recruiting immunosuppressive cells such as M2-type TAMs (8);Yanni Xu et al. This evidence concerns the gene ERBB2 and breast carcinoma.